75 related articles for article (PubMed ID: 38349411)
1. Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer.
Ru CH; Zhuang YB
Comb Chem High Throughput Screen; 2018; 21(10):711-717. PubMed ID: 30686251
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.
Tan Q; Wang D; Yang J; Xing P; Yang S; Li Y; Qin Y; He X; Liu Y; Zhou S; Duan H; Liang T; Wang H; Wang Y; Jiang S; Zhao F; Zhong Q; Zhou Y; Wang S; Dai J; Yao J; Wu D; Zhang Z; Sun Y; Han X; Yu X; Shi Y
Theranostics; 2020; 10(14):6399-6410. PubMed ID: 32483460
[No Abstract] [Full Text] [Related]
5. Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q; Dai L; Wang Y; Liu S; Liang T; Luo R; Wang S; Lou N; Chen H; Zhou Y; Zhong Q; Yang J; Xing P; Hu X; Liu Y; Zhou S; Yao J; Wu D; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2022 Jul; 71(7):1681-1691. PubMed ID: 34817638
[TBL] [Abstract][Full Text] [Related]
6. Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by
data-independent acquisition mass spectrometry.
Chao Y; Jiang W; Wang X; Wang X; Song J; Chen C; Zhou J; Huang Q; Hu J; Song Y
Clin Exp Immunol; 2022 May; 208(1):60-71. PubMed ID: 35348622
[TBL] [Abstract][Full Text] [Related]
7. Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer.
Lu J; Zhang W; Yu K; Zhang L; Lou Y; Gu P; Nie W; Qian J; Xu J; Wang H; Zhong H; Han B
FASEB J; 2022 Aug; 36(8):e22465. PubMed ID: 35867072
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade.
Kang P; Liu D; Li L; Guo X; Ye Y; Li Y; Jiang Q; Lin S; Yuan Q
Cytokine; 2023 Mar; 163():156133. PubMed ID: 36724715
[TBL] [Abstract][Full Text] [Related]
9. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer.
Li S; Na R; Li X; Zhang Y; Zheng T
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188758. PubMed ID: 35809762
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy: it's time to better predict patients' response.
Pilard C; Ancion M; Delvenne P; Jerusalem G; Hubert P; Herfs M
Br J Cancer; 2021 Sep; 125(7):927-938. PubMed ID: 34112949
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker.
Cui L; Zhang F
JAMA Oncol; 2021 Aug; 7(8):1244-1245. PubMed ID: 34110373
[No Abstract] [Full Text] [Related]
12. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.
Marcus L; Fashoyin-Aje LA; Donoghue M; Yuan M; Rodriguez L; Gallagher PS; Philip R; Ghosh S; Theoret MR; Beaver JA; Pazdur R; Lemery SJ
Clin Cancer Res; 2021 Sep; 27(17):4685-4689. PubMed ID: 34083238
[TBL] [Abstract][Full Text] [Related]
13. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT signaling pathway-mediated microRNA-181b promoted blood-brain barrier impairment by targeting sphingosine-1-phosphate receptor 1 in septic rats.
Chen SL; Cai GX; Ding HG; Liu XQ; Wang ZH; Jing YW; Han YL; Jiang WQ; Wen MY
Ann Transl Med; 2020 Nov; 8(21):1458. PubMed ID: 33313203
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
